Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease

Neurobiology of Disease

Volumn 47, Issue 3, 2012, Pages 393-406

  Shin, Eunju ^a   Garcia, Joanna ^b   Winkler, Christian ^b   Björklund, Anders ^a   Carta, Manolo ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cell transplantation; Dopamine D2 receptor; Graft induced dyskinesia; L DOPA induced dyskinesia; Parkinson's disease; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; 5,7 DIHYDROXYTRYPTAMINE; AMPHETAMINE; BUSPIRONE; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; FENFLURAMINE; LEVODOPA; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEUROTRANSMITTER; OXIDOPAMINE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC INNERVATION; BRAIN INJURY; CELL ACTIVITY; CELL TRANSPLANTATION; CORPUS STRIATUM; DISEASE CONTROL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; EMBRYO; ENZYME ACTIVATION; FEMALE; GRAFT FAILURE; GRAFT INDUCED DYSKINESIA; LOW DRUG DOSE; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; RISK REDUCTION; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM;

5,6-DIHYDROXYTRYPTAMINE; ADRENERGIC AGENTS; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BUSPIRONE; CELL COUNT; CREATININE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; LEVODOPA; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONERGIC NEURONS; SEROTONIN RECEPTOR AGONISTS; TIME FACTORS;

EID: 84863427211     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.038     Document Type: Article

References (64)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 1946, 94:239-247.
2. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 2005, 20:932-936.
3. Bardo M.T., Valone J.M., Bevins R.A. Locomotion and conditioned place preference produced by acute intravenous amphetamine: role of dopamine receptors and individual differences in amphetamine self-administration. Psychopharmacology (Berl) 1999, 143:39-46.
4. Bjorklund A. Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr. Opin. Neurobiol. 1992, 2:683-689.
5. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Bjorklund A., Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 2006, 21:657-668.
6. Carlsson T., Carta M., Winkler C., Bjorklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
7. Carlsson T., Carta M., Munoz A., Mattsson B., Winkler C., Kirik D., et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
8. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
9. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S174-S179.
10. Cumming P., Ljubic-Thibal V., Laliberte C., Diksic M. The effect of unilateral neurotoxic lesions to serotonin fibres in the medial forebrain bundle on the metabolism of [3H]DOPA in the telencephalon of the living rat. Brain Res. 1997, 747:60-69.
11. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
12. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
13. Eison A.S., Temple D.L. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am. J. Med. 1986, 80:1-9.
14. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
15. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46months after transplantation for Parkinson's disease. N. Engl. J. Med. 1992, 327:1549-1555.
16. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
17. Garcia J., Carlsson T., Dobrossy M., Nikkhah G., Winkler C. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiol. Dis. 2011, 43:576-587.
18. Garcia J., Carlsson T., Döbrössy M., Nikkhah G., Winkler C. Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation. Exp. Neurol. 2011, 232:270-279.
19. Grealish S., Jonsson M.E., Li M., Kirik D., Bjorklund A., Thompson L.H. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010, 133:482-495.
20. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5:627-628.
21. Herman J.P., Abrous N.D. Dopaminergic neural grafts after fifteen years: results and perspectives. Prog. Neurobiol. 1994, 44:1-35.
22. Jacocks H.M., Cox B.M. Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-d-aspartic acid, glutamic acid and d-amphetamine. J. Pharmacol. Exp. Ther. 1992, 262:356-364.
23. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 2001, 21:2889-2896.
24. Lane E.L., Winkler C., Brundin P., Cenci M.A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 2006, 22:334-345.
25. Lane E.L., Soulet D., Vercammen L., Cenci M.A., Brundin P. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol. Dis. 2008, 32:220-228.
26. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol. Dis. 2009, 35:42-51.
27. Lane E.L., Vercammen L., Cenci M.A., Brundin P. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp. Neurol. 2009, 219:355-358.
28. Lee C.S., Cenci M.A., Schulzer M., Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123(Pt. 7):1365-1379.
29. Lindgren H.S., Ohlin K.E., Cenci M.A. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009, 34:2477-2488.
30. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
31. Lindvall O., Bjorklund A. Cell therapy in Parkinson's disease. NeuroRx 2004, 1:382-393.
32. Lindvall O., Widner H., Rehncrona S., Brundin P., Odin P., Gustavii B., et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 1992, 31:155-165.
33. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 1994, 35:172-180.
34. McMillen B.A., Matthews R.T., Sanghera M.K., Shepard P.D., German D.C. Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J. Neurosci. 1983, 3:733-738.
35. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14years. Nat. Med. 2008, 14:507-509.
36. Monville C., Torres E.M., Dunnett S.B. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 2005, 68:16-23.
37. Munoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
38. Munoz A., Carlsson T., Tronci E., Kirik D., Bjorklund A., Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol. 2009, 219:298-307.
39. Nikkhah G., Olsson M., Eberhard J., Bentlage C., Cunningham M.G., Bjorklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 1994, 63:57-72.
40. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
41. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 2004, 27:58-62.
42. Olanow C.W., Kordower J.H., Lang A.E., Obeso J.A. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann. Neurol. 2009, 66:591-596.
43. Piccini P., Brooks D.J., Bjorklund A., Gunn R.N., Grasby P.M., Rimoldi O., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
44. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
45. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., et al. Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov. Disord. 2011, 26:1997-2003.
46. Ravenscroft P., Chalon S., Brotchie J.M., Crossman A.R. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp. Neurol. 2004, 185:36-46.
47. Redmond D.E., Vinuela A., Kordower J.H., Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol. Dis. 2008, 29:103-116.
48. Rijnders H.J., Slangen J.L. The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity. Psychopharmacology (Berl) 1993, 111:55-61.
49. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
50. Schallert T., Tillerson J. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimising behavioral assessment of outcome. Innovative Models of CNS Disease; From Molecule to Therapy 1999, 131-151. Human Press, Clifton, NJ.
51. Schindler C.W., Carmona G.N. Effects of dopamine agonists and antagonists on locomotor activity in male and female rats. Pharmacol. Biochem. Behav. 2002, 72:857-863.
52. Scuvee-Moreau J., Giesbers I., Dresse A. Electrophysiological and microiontophoretic studies with buspirone: influence on the firing rate of central monoaminergic neurons and their responsiveness to dopamine, clonidine or GABA. Arch. Int. Physiol. Biochim. 1987, 95:439-446.
53. Shoaib M., Baumann M.H., Rothman R.B., Goldberg S.R., Schindler C.W. Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. Psychopharmacology (Berl) 1997, 131:296-306.
54. Soderstrom K.E., Meredith G., Freeman T.B., McGuire S.O., Collier T.J., Sortwell C.E., Wu Q., Steece-Collier K. The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiol. Dis. 2008, 32(2):229-242.
55. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
56. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
57. Winkler C., Bentlage C., Nikkhah G., Samii M., Bjorklund A. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp. Neurol. 1999, 155:165-186.
58. Winkler C., Kirik D., Bjorklund A., Dunnett S.B. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog. Brain Res. 2000, 127:233-265.
59. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
60. Winkler C., Kirik D., Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work?. Trends Neurosci. 2005, 28:86-92.
61. Yeghiayan S.K., Kelley A.E. Serotonergic stimulation of the ventrolateral striatum induces orofacial stereotypy. Pharmacol. Biochem. Behav. 1995, 52:493-501.
62. Yeghiayan S.K., Kelley A.E., Kula N.S., Campbell A., Baldessarini R.J. Role of dopamine in behavioral effects of serotonin microinjected into rat striatum. Pharmacol. Biochem. Behav. 1997, 56:251-259.
63. Zeng B.Y., Iravani M.M., Jackson M.J., Rose S., Parent A., Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol. Dis. 2010, 40:599-607.
64. Zetterstrom T., Herrera-Marschitz M., Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 1986, 376:1-7.